Business Wire

CA-FORESCOUT

6.12.2023 07:02:34 CET | Business Wire | Press release

Share
Critical Infrastructure Still at High Risk: Forescout Research Spotlights 21 New Vulnerabilities

Forescout, a global cybersecurity leader, today released “SIERRA:21 – Living on the Edge,” an analysis of 21 newly discovered vulnerabilities within OT/IoT routers and open-source software components. The report — produced by Forescout Research – Vedere Labs, a leading global team dedicated to uncovering vulnerabilities in critical infrastructure — emphasizes the continued risk to critical infrastructure and sheds light on possible mitigations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205915662/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sierra:21 Infographic (Source: Forescout)

“SIERRA:21 – Living on the Edge” features research into Sierra Wireless AirLink cellular routers and some of its open-source components, such as TinyXML and OpenNDS. Sierra Wireless routers are popular — an open database of Wi-Fi networks shows 245,000 networks worldwide running Sierra Wireless for a variety of applications. For example, Sierra Wireless routers are used for police vehicles connecting to a central network management system or to stream surveillance video, in manufacturing plants for industrial asset monitoring, in healthcare facilities providing temporary connectivity and to manage electric vehicle charging stations. The 21 new vulnerabilities have the potential to stop vital communications that could impact everyday life.

Read the blog: Forescout Vedere Labs discloses 21 new vulnerabilities affecting OT/IoT routers

Forescout Research further finds:

  • The attack surface is expansive with 86,000 vulnerable routers still exposed online. Less than 10% of these routers are confirmed to be patched against known previous vulnerabilities found since 2019.
  • Regions with the highest number of exposed devices includes:
    • 68,605 devices in The United States
    • 5,580 devices in Canada
    • 3,853 devices in Australia
    • 2,329 devices in France
    • 1,001 devices in Thailand
  • Among the 21 vulnerabilities, one has critical severity (CVSS score 9.6), nine have high severity and 11 have medium severity. These vulnerabilities allow attackers to steal credentials, take control of a router by injecting malicious code, persist on the device and use it as an initial access point into critical networks.
  • Patching can’t fix everything. 90 percent of devices exposing a specific management interface have reached end of life, meaning they cannot be further patched.
  • It’s an uphill battle to secure supply chain components. Open-source software elements continue to go unchecked and increase the attack surface of critical devices, leading to vulnerabilities that may be hard for organizations to track and mitigate.

“We are raising the alarm today because there remain thousands of OT/IoT devices representing an increased attack surface that requires attention,” advises Elisa Constante, VP of Research, Forescout Research – Vedere Labs. “Vulnerabilities impacting critical infrastructure are like an open window for bad actors in every community. State-sponsored actors are developing custom malware to use routers for persistence and espionage. Cybercriminals are also leveraging routers and related infrastructure for residential proxies and to recruit into botnets. Our discoveries reaffirm the need for heightened awareness of the OT/IoT edge devices that are so often neglected.”

Sierra Wireless and OpenDNS have issued patches for the identified vulnerabilities. TinyXML is an abandoned open source project, so the upstream vulnerabilities will not be fixed and must be addressed downstream.

For more information, download the full report, “SIERRA:21 – Living on the Edge,” now at https://www.forescout.com/resources/sierra21-vulnerabilities.

Additional Resources:

About Forescout

Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231205915662/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye